46 results
6-K
EX-99.8
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
).
Mission
In accordance with articles 7:180 and 7:191 and 7:193 of the Code of companies and associations (hereinafter ‘CCA’), in our capacity as statutory … the justification of the issuance price.
Basis for the conclusion
We carried out our mission in accordance with the normative framework applicable
6-K
EX-99.6
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
by-laws.
Responsibilities of the statutory auditor
In the context of our mission and in accordance with the Belgian standard (version revised 2020 … have at our disposition during the performance of our mission.
Statement related to independence
Our audit firm and our network did not provide
6-K
EX-99.2
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
such statements, unless specifically required by law or regulation. Our Company Our Vision and Mission Our Vision Transforming patient outcomes through life … -changing science and innovation for more years of life and quality of life. Our Mission We accelerate transformational innovation through the relentless
6-K
EX-99.15
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
sustainability in the corporate objectives, through stand-alone objectives and/or through the overarching mission of improving patients’ lives worldwide
6-K
EX-99.1
GLPG
Galapagos NV
29 Mar 24
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
6:14am
of Directors,” said Mr. Dickinson. “I look forward to working with the team and to contributing to the company’s mission of pioneering on behalf of patients
6-K
EX-99.1
cxu13vcg0
6 Feb 24
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
6:00am
6-K
EX-99.1
4m2 5mbnv9bhqcnbvw
4 Jan 24
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
4:05pm
S-8
EX-4.1
pmkqm
4 Dec 23
Registration of securities for employees
5:16pm
6-K
EX-99.1
e6qd8ms959ta 1xkm7d
2 Nov 23
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
7:15am
6-K
EX-99.2
moa54h gkn
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.1
oneez2lm oxzu5rv1q
15 Jun 23
Galapagos appoints Thad Huston as Chief Financial Officer and Chief Operating Officer
5:03pm
6-K
EX-99.1
0danm
13 Jun 23
Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board
7:53am
S-8
EX-4.1
don9mk a19od33s1apeu
12 Dec 22
Registration of securities for employees
4:08pm
6-K
EX-99.1
f17f0z41 bcx2eo8g1s
14 Nov 22
Current report (foreign)
6:05am
6-K
EX-99.1
dyry hylyb32
4 Nov 22
Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022
4:57pm
6-K
EX-99.1
o7szrm058l4ny
23 Jun 22
Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies
11:21am
6-K
EX-3.1
fbpqlob
11 May 22
Current report (foreign)
4:05pm
6-K
EX-99.2
wohlym5h2btcdu
6 May 22
Current report (foreign)
5:18pm
6-K
EX-99.1
t67a krij
6 May 22
Current report (foreign)
5:18pm